Verastem to Present at Upcoming Scientific and Investor Conferences

  Verastem to Present at Upcoming Scientific and Investor Conferences

Business Wire

CAMBRIDGE, Mass. -- September 18, 2013

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to
treat cancer by the targeted killing of cancer stem cells, announced that
members of the Company will present at multiple upcoming scientific and
investor conferences. The Verastem presentation information is as follows:

Advances in Ovarian Cancer Research: From Concept to Clinic Conference
Date: September 18-21, 2013 at the J.W. Marriott Marquis in Miami, FL

Presentation 1:
Title:          FAK inhibitors VS-6063 and VS-4718 preferentially target
                ovarian cancer stem cells
Session:        Poster Session A, Thursday, September 19, 4:30 p.m. – 6:30
Location:       Met Ballroom 2-4, Met Ballroom 5-7
Abstract:       A39

Presentation 2:
Title:          Predictive biomarkers for FAK inhibitor sensitivity in ovarian
Session:        Poster Session B, Friday, September 20, 12:30 p.m. – 2:30 p.m.
Location:       Met Ballroom 2-4, Met Ballroom 5-7
Abstract:       B13

Cancer Advance at Harvard Medical
Date: September 19, 2013 at Harvard Medical School in Boston, MA

Summary: Verastem executives will join panel discussions throughout the day,
addressing industry leaders from Eli Lilly, Harvard University, Johnson &
Johnson, Mass General Hospital, and Pfizer among others. President and CEO
Robert Forrester will moderate the investor-focused panel “Betting on
Oncology: Investor Perspectives” and Chief Business Officer Dan Paterson will
join colleagues to discuss efficacy and pricing issues on the “Regulatory and
Reimbursement Pressures for Cancer Drugs” panel. Chief Medical Officer Joanna
Horobin and Head of Research Jonathan Pachter will also address the audience
in two Q&A discussions that will focus on clinical trials in oncology. In
addition, Verastem will also be presenting two trials in progress posters
describing the registration-directed COMMAND study in mesothelioma and the
ongoing combination study of paclitaxel and defactinib in patients with
ovarian cancer.

Joint MipTec / BioValley Keynote Address
Date: September 24, 2013 at 1:40 p.m. CET at the Congress Center Basel, in
Basel, Switzerland

Presenter: Christoph Westphal, M.D., Ph.D., Verastem Executive Chairman

Title: “Drug Innovation in Biotech: Alnylam, Momenta, Sirtris, Verastem”

Summary: Dr. Christoph Westphal is delivering the keynote address to the
MipTec conference in Basel. In 2012 the keynote was presented by the Head of
Research and Development at Regeneron, Dr. George Yancopoulos. This year’s
keynote by Dr. Westphal will describe how over the last 13 years, discoveries
at MIT and Harvard have been turned into several public biotechnology
companies, valued at several hundred million, to several billion in market
capitalization. In each case, the team has been motivated by a desire to
develop important new medicines for patients with serious illnesses. Working
with great people, on fundamentally important novel science, with the chance
to make transformative medicines can, if you are lucky, also create value for
shareholders. Some of these unifying themes and learnings are captured in
briefly describing the similar, and divergent, paths of four companies Dr.
Westphal has founded as CEO: Alnylam, Momenta, Sirtris, and Verastem.

BioCentury’s 2013 Newsmakers in the Biotech Industry Conference
Date: September 27, 2013 at 9:30 a.m. ET at the Millennium Broadway Hotel in
New York, NY

Webcast: A webcast of the Newsmakers presentation can be accessed by visiting
the investors section of the Company’s website at A replay
of the webcast will be archived on the Verastem website for 30 days following
the presentation date.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat
cancer by the targeted killing of cancer stem cells. Cancer stem cells are an
underlying cause of tumor recurrence and metastasis. Verastem is developing
small molecule inhibitors of signaling pathways that are critical to cancer
stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more
information, please visit

Forward-looking statements:

Any statements in this press release about future expectations, plans and
prospects for the Company constitute forward-looking statements. Actual
results may differ materially from those indicated by such forward-looking
statements. The Company anticipates that subsequent events and developments
will cause the Company’s views to change. However, while the Company may elect
to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so.


Verastem, Inc.
Brian Sullivan, 617-252-9314
Press spacebar to pause and continue. Press esc to stop.